Clinical trial
GTA-Glyceryltriacetate for Canavan Disease
NCT00278707 · Sheba Medical Center, Other · Unknown status
Key facts
| NCT number | NCT00278707 |
|---|---|
| Title | GTA-Glyceryltriacetate for Canavan Disease |
| Official title | Phase 1 Treatment With GTA in Two Infant With Canavan Disease |
| Lead sponsor | Sheba Medical Center, Other |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Infantile Canavan Disease, Deficiency Disease, Aspartoacylase |
| Intervention type | Drug |
| Interventions | GTA: Glyceryltriacetate |
| Enrollment | 5 |
| Start date | Jan 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Jan 18, 2006 |
| Last update posted | Aug 15, 2006 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: